<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment</h1>
  <ul>
<li>The current share price of $94.03, remaining just 4.6% below the consensus price target of $98.63, indicates that the market perceives the stock as fairly priced, likely reflecting the anticipated earnings and market pos</li>
<li>Over a longer-term period of three years, Medtronic delivered a total shareholder return of 15.85%, illustrating steady growth.</li>
<li>Concerning the revenue and earnings forecasts, the positive sentiment from Medtronic's new product initiatives aligns with analysts' expectations of annual revenue growth of 5.4% and margins reaching 15.6% over the next</li>
<li>This growth is contextualized by its recent 18.7% increase in earnings over the past year, which exceeded the broader medical equipment industry's 12.6% growth.</li>
<li>Despite underperforming the broader US market over the past year, spurred by a 18.5% overall market return, Medtronic's focused initiatives and innovations aim to sustain its market relevance.</li>
<li>Medtronic has recently initiated the ELEVATE-HFpEF study focusing on heart failure treatment, which, alongside other product developments and strategic initiatives, coincides with a positive quarter-end price movement of</li>
<li>You should learn about the 1 warning sign we've spotted with Medtronic.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/medtronic-mdt-launches-global-study-171855891.html">Source</a> · 2025-09-15T17:18:55+00:00</p>
</body>
</html>